North America Cold Sore Treatment Market is expected to grow with the CAGR of 6.0% in the forecast period of 2021 to 2028. The years considered for study are as mentioned below.

Access Full Report @ https://www.databridgemarketresearch.com/reports/north-america-cold-sore-treatment-market

North America cold sore treatment market is a highly consolidated market, which includes specific numbers of key players. The market has witnessed increased strategic developments owing to favorable market scenario.   

Major players dealing in the North America cold sore treatment market are introducing a wide range of new products and adopting strategic initiatives, such as acquisitions, agreements, business expansions, and awards and recognitions, into the market. This helps companies to maximize the sales with enhanced product portfolio.  

For instance:

• In June 2010, GlaxoSmithKline plc declared an agreement with Medivir for commercialization of Xerclear for OTC in global markets. Xerclear is the only topical herpes treatment clinically proven to prevent the appearance of cold sore lesions. The initiative by the company resulted in exclusive benefit to commercialize and deliver non-prescribed Xerclear across various markets. This resulted in brand recognition, enhancement in product portfolio, and positive growth in the market.  

GlaxoSmithKline plc is the dominating player in the North America cold sore treatment market. Other key players existing in the market are Merix Pharmaceutical Corp., Amneal Pharmaceuticals LLC, Sun Pharmaceutical Industries Ltd., Glenmark Pharmaceuticals, Inc., U.S.A. (a subsidiary of Glenmark Pharmaceutical Ltd.), Zydus Pharmaceuticals, Inc. (a subsidiary of Zydus Cadila), Cipla Limited, Ortho Dermatologics’ (a division of Bausch Health Companies Inc.), FOUNDATION CONSUMER HEALTHCARE, Sqaurex, Teva Pharmaceuticals USA, Inc. (a subsidiary of Teva Pharmaceutical Industries Ltd.), Viatris Inc., Aurobindo Pharma USA (a subsidiary of Aurobindo Pharma), Novartis AG, Jubilant Cadista (a subsidiary of Jubilant Life Sciences Ltd.), Hikma Pharmaceuticals PLC, Apotex Inc., HRA Pharma among others.

GlaxoSmithKline plc.

GlaxoSmithKline plc. is headquartered in Brentford, U.K. The company was founded in the year 1715. It is focused on the delivery of strategic priorities, which aim to increase growth, reduce risk, and improve long term financial performance. The company operates its business through three business segments including pharmaceuticals, vaccines, and consumer healthcare in which consumer healthcare is the market focused segment. The company is engaged in manufacturing and marketing of several products including prescription medicines, vaccines, consumer healthcare products, ViiV healthcare and stiefel dermatology in which consumer healthcare products is the market focused category.

For instance,

• In June 2010, GlaxoSmithKline plc. had declared an agreement with Medivir for commercialization of Xerclear for OTC in global markets. Xerclear is the only topical herpes treatment clinically proven to prevent the appearance of cold sore lesions. The initiative by the company had resulted in exclusive benefit to commercialize and deliver non-prescribed Xerclear across various markets. It had resulted in brand recognition, enhancement in product portfolio, and positive growth in the market

The company has wide presence across Asia-Pacific, Europe, Middle East and Africa, and Americas. Italso has various subsidiary companies including GlaxosmithKline Pharmaceuticals Ltd (India), Tesaro (U.S.), GlaxoSmithKline Pakistan (Pakistan), Stiefel Laboratories (U.S.), and Allen & Hanburys (U.K.) among others.  

Ortho Dermatologics (A Division of Bausch Health Companies Inc.)

Ortho Dermatologics (A Division of Bausch Health Companies Inc.) is headquartered in New Jersey, U.S. The company focuses on dermatology field through its honest actions and ongoing heritage of helping improve patient lives. The company has wide product categories including Altreno, Arazlo, Bryhali, Clindagel, Duobrii, Elidel, Jublia, Locoid Lotion, Loprox Shampoo, Luzu, Noritate, Onexton, Retin-a Micro, Siliq, Solodyn, Xerese, Ziana, Zovirax, and Zyclara among which Altreno, Zovirax, and Xerese are the market focused categories.

• In February 2020, Ortho Dermatologics announced Aspire higher scholarship program 2020. In this program, nine students who have been treated for a dermatologic problem can win scholarship of USD 10,000 for their academics. This will help the company to make healthy relationships with customers and will benefit the company.

The company has presence across the U.S.

FOUNDATION CONSUMER HEALTHCARE

FOUNDATION CONSUMER HEALTHCARE was founded in 2014 and is headquartered in Pennsylvania, the U.S. The company is focusing on developing a portfolio of OTC products to improve consumer life. It is engaged in manufacturing of products including Plan B One-Step, Campho-Phenique, St. Joseph Low Dose Aspirin, and Bronkaid, in which Campho-Phenique is the market focused category.

• In October 2020, FOUNDATION CONSUMER HEALTHCARE acquired seven brands from GSK Consumer Healthcare via its Foundation Consumer Brands Company, which is under common management of FOUNDATION CONSUMER HEALTHCARE. With this acquisition, the company is focusing on increasing its product portfolio and penetrating the OTC market.

The company has presence across U.S.